185 related articles for article (PubMed ID: 35263336)
1. The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response.
M A M; Kim JY; Pan CH; Kim E
PLoS Comput Biol; 2022 Mar; 18(3):e1009919. PubMed ID: 35263336
[TBL] [Abstract][Full Text] [Related]
2. Adaptive therapy.
Gatenby RA; Silva AS; Gillies RJ; Frieden BR
Cancer Res; 2009 Jun; 69(11):4894-903. PubMed ID: 19487300
[TBL] [Abstract][Full Text] [Related]
3. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
[TBL] [Abstract][Full Text] [Related]
4. Modeling the effect of acquired resistance on cancer therapy outcomes.
Masud MA; Kim JY; Kim E
Comput Biol Med; 2023 Aug; 162():107035. PubMed ID: 37276754
[TBL] [Abstract][Full Text] [Related]
5. Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models.
Kim E; Brown JS; Eroglu Z; Anderson ARA
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669315
[TBL] [Abstract][Full Text] [Related]
6. In Silico Investigations of Multi-Drug Adaptive Therapy Protocols.
Thomas DS; Cisneros LH; Anderson ARA; Maley CC
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681680
[TBL] [Abstract][Full Text] [Related]
7. Investigation of realistic PET simulations incorporating tumor patient's specificity using anthropomorphic models: creation of an oncology database.
Papadimitroulas P; Loudos G; Le Maitre A; Hatt M; Tixier F; Efthimiou N; Nikiforidis GC; Visvikis D; Kagadis GC
Med Phys; 2013 Nov; 40(11):112506. PubMed ID: 24320465
[TBL] [Abstract][Full Text] [Related]
8. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition.
Strobl MAR; Gallaher J; West J; Robertson-Tessi M; Maini PK; Anderson ARA
Commun Med (Lond); 2022; 2():46. PubMed ID: 35603284
[TBL] [Abstract][Full Text] [Related]
9. Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes.
Leighow SM; Landry B; Lee MJ; Peyton SR; Pritchard JR
Cell Mol Bioeng; 2022 Oct; 15(5):521-533. PubMed ID: 36444351
[TBL] [Abstract][Full Text] [Related]
10. Effective dose window for containing tumor burden under tolerable level.
Masud MA; Kim JY; Kim E
NPJ Syst Biol Appl; 2023 May; 9(1):17. PubMed ID: 37221258
[TBL] [Abstract][Full Text] [Related]
11. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
Hirakawa A
Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
[TBL] [Abstract][Full Text] [Related]
12. Tumour Growth Mechanisms Determine Effectiveness of Adaptive Therapy in Glandular Tumours.
Tan RZ
Interdiscip Sci; 2024 Mar; 16(1):73-90. PubMed ID: 37776475
[TBL] [Abstract][Full Text] [Related]
13. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
Wages NA; Fadul CE
Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
[TBL] [Abstract][Full Text] [Related]
14. Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment.
West J; Ma Y; Newton PK
J Theor Biol; 2018 Oct; 455():249-260. PubMed ID: 30048718
[TBL] [Abstract][Full Text] [Related]
15. Adaptive Therapy and the Cost of Drug-Resistant Mutants.
Wodarz D
Cancer Res; 2021 Feb; 81(4):811-812. PubMed ID: 33822746
[TBL] [Abstract][Full Text] [Related]
16. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
17. Improved adaptive randomization strategies for a seamless Phase I/II dose-finding design.
Yan D; Wages NA; Dressler EV
J Biopharm Stat; 2019; 29(2):333-347. PubMed ID: 30451068
[TBL] [Abstract][Full Text] [Related]
18. Optimizing Adaptive Therapy Based on the Reachability to Tumor Resistant Subpopulation.
Wang J; Zhang Y; Liu X; Liu H
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771426
[TBL] [Abstract][Full Text] [Related]
19. Spatial chaos and complexity in the intracellular space of cancer and normal cells.
Pham TD; Ichikawa K
Theor Biol Med Model; 2013 Oct; 10():62. PubMed ID: 24152322
[TBL] [Abstract][Full Text] [Related]
20. Long range personalized cancer treatment strategies incorporating evolutionary dynamics.
Yeang CH; Beckman RA
Biol Direct; 2016 Oct; 11(1):56. PubMed ID: 27770811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
